SCHEMBL5128384

SCHEMBL5128384

CCc1ccn2c(NCc3ccccc3OC)c(-c3ccc(C#Cc4ccccc4)s3)nc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
ADORA3 P0DMS8 2/20 0.36
ADORA2A P29274 2/20 0.36
ADORA2B P29275 2/20 0.36
ADORA1 P30542 2/20 0.36
TLR9 Q9NR96 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
KCNN3 Q9UGI6 1/20 0.35
ACACB O00763 1/20 0.34
LMNA P02545 2/20 0.34
KDM1A O60341 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5127691 0.91 GAA (0.48) NR1H4SMN1; SMN2GAAMAPTKDM4E
SCHEMBL5128007 0.88 NR1H4 (0.52) NR1H4SMN1; SMN2GAAMAPTKDM4E
SCHEMBL5122315 0.88 NR1H4 (0.44) NR1H4SMN1; SMN2GAAMAPTKDM4E
SCHEMBL5122351 0.82 SMN1; SMN2 (0.38) SMN1; SMN2GAAMAPTKDM4EALDH1A1
SCHEMBL5117440 0.81 NR1H4 (0.54) NR1H4SMN1; SMN2GAAMAPTKDM4E
SCHEMBL5130390 0.79 GAA (0.55) NR1H4SMN1; SMN2GAAMAPTKDM4E
SCHEMBL5121630 0.78 NR1H4 (0.45) NR1H4SMN1; SMN2GAAMAPTKDM4E
SCHEMBL5127028 0.77 GAA (0.56) NR1H4SMN1; SMN2GAAMAPTKDM4E
SCHEMBL5127654 0.76 NR1H4 (0.51) NR1H4SMN1; SMN2GAAMAPTKDM4E
SCHEMBL5117116 0.76 NR1H4 (0.48) NR1H4SMN1; SMN2GAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
EP-1791840-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS Grünenthal GmbH (DE) 2007-06-06 EP claimed
WO-2006029980-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS Grünenthal GmbH (DE) 2006-03-23 WO claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS NR1H4 2683/4885SMN1; SMN2 1463/4885GAA 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.